Evidence map›Paper›PMID 42373846›Full record

ArticleBritish journal of cancer2026

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

Nicola S Meagher, Kami K White, Lynne R Wilkens, Hoda Anton-Culver, Elisa V Bandera, Michael E Carney, Daniel W Cramer, Kara L Cushing-Haugen, Anna DeFazio, Jennifer A Doherty and 36 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Nicola S Meagher *The Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-9134-2118
Kami K White *Population Sciences in the Pacifi c Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, HI, USA.
Lynne R WilkensPopulation Sciences in the Pacifi c Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, HI, USA.
Hoda Anton-CulverDepartment of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0002-8789-2755
Michael E CarneyDepartment of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Kara L Cushing-HaugenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Anna DeFazioThe Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-0057-4744
Jennifer A DohertyDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-1454-8187
Aleksandra Gentry-MaharajDepartment of Women's Cancer, Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.
Ellen L GoodeDepartment of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9094-8326
Marc T GoodmanCancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Beth Y KarlanDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-9451-2933
Scott H KaufmannDepartments of Medicine and Molecular Pharmacology, Mayo Clinic, Rochester, MN, USA.
Linda E KelemenCommunicable Disease Epidemiology Section, South Carolina Department of Public Health, Columbia, SC, USA.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
Jennifer M KoziakAlberta Health Services-Cancer Care, Calgary, AB, Canada.
Loic Le MarchandPopulation Sciences in the Pacifi c Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, HI, USA.
Jenny LesterDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.
Valerie McGuireDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
Usha MenonUCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID http://orcid.org/0000-0003-3708-1732
Francesmary ModugnoDepartment of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Paul D P PharoahDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA.ORCID http://orcid.org/0000-0001-8494-732X
Malcolm C PikeDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Bo QinCancer Prevention and Control Program, Rutgers Cancer Institute, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0003-2110-6050
Harvey A RischChronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Joseph H RothsteinDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Danja SarinkPopulation Sciences in the Pacifi c Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, HI, USA.
Weiva SiehDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Helen SteedDepartment of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Department of Obstetrics and, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Pamela J ThompsonSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Linda J TitusDartmouth Cancer Center, Lebanon, NH, USA.
Toon Van GorpDivision of Gynaecologic Oncology, Leuven Cancer Institute, University Hospital Leuven and KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-2564-721X
Alice S WhittemoreDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
Stacey J WinhamDepartment of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8492-9102
Susan J JordanSchool of Public Health, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-4566-1414
Anna H WuDepartment of Population Health and Public Health Sciences, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Penelope M WebbPopulation Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0003-0733-5930
AOCS Group
Lauren C PeresDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-6620-8600
Melissa A MerrittThe Daffodil Centre, The University of Sydney and Cancer Council NSW, Sydney, NSW, Australia. melissa.merritt@sydney.edu.au.ORCID http://orcid.org/0000-0002-5067-6119

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8M
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSK07CA080668 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MODUGNO, FRANCESMARY · 2000 to 2005
$661k
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and OutcomesR21CA267050 · NCI · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MODUGNO, FRANCESMARY · 2022 to 2023
$408k
NCI NIH HHS K07 CA080668NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA248288NCI NIH HHS R21 CA267050
6 · The paper itself

Abstract

backgroundPrior studies have examined survival in patients with epithelial ovarian cancer (EOC); however, few consider race and ethnicity, particularly disaggregating Asian and Native Hawaiian/Pacific Islander women.

methodsWe analysed data from 18 Ovarian Cancer Association Consortium studies, including women with EOC from Asian (n = 697), non-Hispanic Black (n = 267), Hispanic (n = 492), Native Hawaiian/Pacific Islander (n = 98) and non-Hispanic White (n = 12,998) racial and ethnic groups. We ran Cox proportional hazards models estimating overall survival by race and ethnicity, adjusting for age, stage, year of diagnosis, and histotype, with fully adjusted models accounting for body mass index, smoking, and postmenopausal hormone use. We also examined associations between hormone-related factors and family history and overall survival by race and ethnicity, testing for heterogeneity.

resultsCompared to non-Hispanic White women with EOC, Native Hawaiian/Pacific Islander and non-Hispanic Black women had poorer overall survival (Hazard Ratios, HR = 1.58, 95% CI = 1.16-2.16, and HR = 1.31, 95% CI = 1.12-1.54, respectively). The association was more pronounced for Native Hawaiian/Pacific Islander women with high-grade serous carcinoma (HR = 2.00, 95% CI = 1.37-2.92). There was no significant heterogeneity in the associations between epidemiological factors and survival by racial and ethnic groups (p ≥ 0.31). DISCUSSION: Native Hawaiian/Pacific Islander and non-Hispanic Black women with EOC had poorer survival, highlighting the need to address disparities in outcome.

Indexed as

Neoplasms, Glandular and EpithelialOvarian NeoplasmsAgedCarcinoma, Ovarian EpithelialEthnicityFemaleHumansMiddle AgedNative Hawaiian or Pacific IslanderProportional Hazards ModelsWhite

Identifiers

PMID42373846
PMCPMC13578740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.